Oral Dipyridamole-Associated Circulatory Collapse.

Area of Science:

• Pharmacology
• Cardiology
• Neurology

Background:

• Extended-release dipyridamole combined with aspirin is prescribed for secondary stroke prevention.
• The precise molecular mechanisms of dipyridamole's cardiovascular effects are not fully understood.
• Known adverse events include headache, bleeding, and gastrointestinal issues, with rare severe events like cardiogenic shock from IV dipyridamole.

Observation:

• A 72-year-old male patient experienced a transient ischemic attack.
• Following oral administration of 200 mg extended-release dipyridamole, the patient suffered circulatory collapse.
• This represents the first documented case of circulatory collapse linked to oral dipyridamole intake.

Findings:

• The case highlights a potential severe cardiovascular adverse effect of orally administered extended-release dipyridamole.
• Review of molecular mechanisms suggests potential pathways for dipyridamole's impact on the cardiovascular system.
• This finding contrasts with its typical use and known side effect profile.

Implications:

• Clinicians should be aware of the potential for severe cardiovascular events, including circulatory collapse, with oral dipyridamole, even at standard doses.
• Further research into dipyridamole's cardiovascular pharmacodynamics is warranted.
• This case may prompt re-evaluation of prescribing guidelines and patient monitoring for extended-release dipyridamole.